drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous chimeric antigen receptor T-cell therapy engineered to express an IL13Rα2-specific CAR. Upon binding IL13Rα2 on glioma cells, CAR signaling (CD3ζ with costimulatory domains) activates cytotoxic T-cell responses and cytokine secretion to kill tumor cells; delivered via intraventricular infusions.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intracerebroventricular
drug_mechanism_of_action
Autologous T cells engineered to express an IL13Rα2-specific CAR (CD3ζ with costimulatory domains). Binding IL13Rα2 on glioma cells triggers CAR signaling, activating T-cell cytotoxicity and cytokine release to lyse IL13Rα2-positive tumor cells; administered via intraventricular infusions.
drug_name
IL13Rα2 CAR-T
nct_id_drug_ref
NCT06355908